Medicine is on the verge of a new era, and pharmacology is its pulse. March 2025 was a month of big announcements, scientific breakthroughs, and ethical dilemmas. Here are the most important events that shook the pharmaceutical world.
The American company NeuroCore announced the successful completion of the third phase of clinical trials of gene therapy for patients with Alzheimer’s disease. The drug NC-β42 showed an improvement in cognitive functions in 62% of patients. It is expected that the application for registration will be submitted to the FDA in April. If approved, it will be the first such drug on the market.
State-owned enterprise “Biopharma” has signed an agreement with a German concern to launch joint production of new-generation vaccines based on mRNA technologies. Production will start in June, with a focus on vaccines against influenza, HPV and hepatitis B. This is a strategic step towards pharmaceutical independence of Ukraine.
The WHO’s annual report notes a rise in the number of patients being prescribed antidepressants without sufficient justification, especially among young people in Europe. The organization calls for the implementation of psychiatric screening protocols before prescribing psychotropic drugs. This has sparked a debate about the line between caring and the pharmacology of emotions.
Japan’s Ministry of Health has approved the world’s first drug developed using CRISPR-Cas9 technology, EditCellin, to treat a rare form of anemia, opening up new horizons for gene editing in therapeutic practice.
In March, analysts reported a 15% increase in investments in the development of herbal medicines. Curcumin, cannabinoids and ashwagandha are attracting particular attention. It is expected that new standardized preparations based on these substances will appear in 2025-2026.
Pharmacology is changing rapidly: from molecules to microscopic scissors, from chemistry to bioengineering. But behind every pill is a question: does it really cure, or just calm fear? In March, we saw both hope and caution. It’s time not only to swallow, but also to ask questions.
Technical analysis of depolarization (TDP) in an ERVO stack. Economics of organic waste processing and EROEI indicators. Expert assessment by Oleksandr Mospanenko.
Resistance analysis of ESKAPE strains.. Methodology by A. Demchenko for C-level Pharma.
Scientific justification for the reclamation of technozems. Bioremediation based on glauconite according to patents of the AVELIFE Institute. Expert assessment by Timur Levda for agricultural holdings
